Phase I clinical trial of ormaplatin (tetraplatin, NSC 363812)

Anti-Cancer Drugs

Volumn 5, Issue 5, 1994, Pages 520-526

  O'Rourke, T J ^a   Weiss, G R ^a   New, P ^a   Burris III, H A ^a   Rodriguez, G ^a   Eckhardt, J ^a   Hardy, J ^a   Kuhn, J G ^a   Fields, S ^a   Clark, G M ^a   Von Hoff, D D ^a  

^a BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

neurotoxicity; ormaplatin; phase I trial

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; LORAZEPAM; METOCLOPRAMIDE; PLATINUM; TETRAPLATIN;

ADULT; AGED; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BLOOD LEVEL; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SOLID TUMOR; SURAL NERVE; URINE LEVEL; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BLOOD CELL COUNT; BONE MARROW DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; SPECTROPHOTOMETRY, ATOMIC; VOMITING;

EID: 0028034914     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199410000-00002     Document Type: Article

References (0)